RESET ECS A Bonner Biotech Brand
Client Education Document
Conventional & Alternative Medicine
Guidance Series
Volume 02 · Phytocannabinoids for Skin & Connective Tissue

Beyond the Surface

A current, science-led approach: activating the endocannabinoid system with rare phytocannabinoids to support the skin, and the living connective tissue beneath it.

Author Barry Bonner  ·  Issued by Reset ECS
BON-DERM · 061126-v05
Orientation

In Brief

  • The endocannabinoid system (ECS) is the body’s largest regulatory network, and the skin runs its own complete version of it.
  • It reaches past the skin into the fascia, where cannabinoid receptors and the cells that make hyaluronan respond directly to cannabinoids.
  • A single molecule like CBD cannot meaningfully activate this network; a broad spectrum of rare cannabinoids, delivered in oil, is designed to.
  • This is a current, science-grounded approach to skin and connective-tissue health, not a future promise.
Part I · The Idea
01 / The Premise

The Surface Is Only Half the Story

Almost everything sold as skincare works at the surface. Retinol speeds the shedding of cells. Hyaluronic acid sits on top of the skin and holds water. Vitamin C donates an electron. Each does one thing to one layer. None of them speak to the system that actually decides how skin behaves: how quickly it renews, how fiercely it inflames, how well it holds moisture, and how resiliently it repairs.

That system is the endocannabinoid system, or ECS, the body’s master regulator of balance.4 Activating it with rare phytocannabinoids does not patch a single symptom; it supports the underlying machinery of healthy tissue, from cell-cycle control and inflammation to collagen, hydration, and barrier integrity. And, as the science now makes clear, that machinery does not stop at the skin. It runs all the way down into the fascia, the connective architecture that gives skin its firmness, contour, and bounce.19

Most skincare treats the surface. The endocannabinoid system regulates the system.

This understanding was a long time coming, and not by accident. Medicinal hemp was removed from the U.S. Pharmacopeia in 1942, and federal cultivation was only reinstated in 2019, a near-century gap during which the ECS’s role in skin and tissue homeostasis went largely unexplored. Our work begins from the other side of that gap. Drawing on four years of research and development, including the creation of a pioneering beauty facial serum, and on the established science of the ECS, our broad-spectrum, oil-based formulations are built to engage the system where it lives: in the skin, and in the tissue beneath it. While our wider line extends to additional topicals, suppositories, and sublinguals, this document focuses on the topical story. What follows is the science behind it.

02 / The Network

A Regulatory System Unlike Any Other

The endocannabinoid system is not one system among many. By reach, it is the largest signalling network the body has.

First characterised in the late 1980s and often called the body’s “master neuromodulator,” the ECS exists to maintain homeostasis, or balance, across an astonishing range of functions: inflammation, pain, immune response, mood, memory, repair, and more.2 Its principal receptor, CB1, is the single most abundant G-protein-coupled receptor in the human brain, and cannabinoid receptors appear in virtually every tissue and organ, including the skin and the fascia.34 No other regulatory network is so widely distributed, nor so directly responsible for keeping so many systems in balance at once.

01

The Most Abundant Receptors

CB1 is the most abundant G-protein-coupled receptor in the brain, and cannabinoid receptors are among the most widespread of any in the body.

02

Body-Wide Presence

ECS receptors are found in the skin, fascia, immune system, nervous system, gut, bone, muscle, and fat, a footprint no other system rivals.

03

On-Demand & Self-Limiting

Endocannabinoids are produced only where and when they are needed, then rapidly broken down: precise regulation, not blunt, constant signalling.

04

A True Master Regulator

Rather than driving one function, the ECS continuously tunes inflammation, repair, hydration, and barrier balance toward equilibrium.

05

Lipid-Native By Design

The system runs on fat-derived messengers, which is why an oil-based delivery vehicle is uniquely suited to support it.

03 / Inside the System

How It Actually Works

The ECS has three working parts: the messengers, the receptors they bind, and the enzymes that switch the signal off. Together they form a continuous feedback loop that restores equilibrium whenever stress, injury, or the environment disturbs it. In the skin, that means modulating barrier function, sebum production, neuroimmune responses, and repair, the systems behind hydration, defence, and the management of inflammation.4

AEA
2-AG

The Messengers

Anandamide and 2-AG, the body’s own cannabinoids, are made on demand from membrane fats, bind their receptors to restore balance, then are quickly cleared.1

CB1

Mood, Nerves & Skin

Concentrated in the nervous system but also present in the skin, CB1 helps regulate sensation and inflammatory tone, and influences keratinocyte growth and sebocyte activity.9

CB2

Immunity & Repair

Found in immune cells, keratinocytes, fibroblasts, and the fasciacytes of connective tissue, CB2 governs inflammation and wound healing, the key target in topical care.19

FAAH
MAGL

The Off-Switch

These enzymes degrade the body’s endocannabinoids once their work is done, preventing prolonged activation and keeping the signal precise.

Imbalance stress, UV, injury Endocannabinoids made on demand Bind CB1 / CB2 & TRP / PPAR Balance restored FAAH & MAGL clear the signal: precise, self-limiting
The ECS works as a feedback loop: it acts only when balance is disturbed, then switches itself off.

When the System Runs Low

When the body’s production or regulation of endocannabinoids falters, a state researchers call Clinical Endocannabinoid Deficiency, the consequences surface across many systems at once: heightened inflammation, hypersensitivity, immune dysregulation, and slower repair.5 In the skin, low endocannabinoid tone has been associated with conditions marked by disrupted barrier function and neuroimmune imbalance. Modern life appears to deplete it: genetic variation affecting ECS enzymes and receptors, chronic stress, persistent inflammation, diets low in the essential fatty acids the system is built from, sedentary routines, environmental toxins and pollution, and insufficient sleep. The near-total removal of dietary phytocannabinoids over the last century may have compounded the effect. Restoring that tone is precisely what targeted phytocannabinoid support is designed to do.

04 / The Skin’s Own System

Your Skin Runs Its Own Endocannabinoid System

The ECS is not something we borrow from the brain when we apply a topical. The skin operates its own, complete endocannabinoid network. Researchers have called it the “c(ut)annabinoid” system: every major skin cell type makes endocannabinoids, carries the receptors to respond to them, and uses them to keep itself in balance.4 This is why phytocannabinoids have somewhere to act the moment they reach the skin.

Sebaceous Glands

The oil glands are ECS-controlled. Cannabidiol acts as a sebostatic, calming excess oil and inflammation in sebocytes. It is one of the clearest mechanisms behind cannabinoids and clearer, less blemish-prone skin.26

Hair Follicles

The follicle is exquisitely sensitive to endocannabinoid tone, which helps govern the growth cycle, a target for both hair health and unwanted-growth concerns.4

Keratinocytes

The barrier-forming cells use ECS signalling to balance proliferation against differentiation, the rhythm behind smooth, intact, well-renewed skin.9

Immune & Pigment Cells

Resident immune cells and melanocytes carry cannabinoid receptors too, linking the ECS to inflammation, sensitivity, and pigmentation.18

In other words, ECS-targeted skincare is not introducing a foreign mechanism. It is speaking the skin’s own native language, supporting a regulatory system the skin already runs for itself.

Part II · Where Most Products Fall Short
05 / The Market’s Mistake

Why CBD Alone Cannot Activate the ECS

The modern hemp and CBD market has been built almost entirely around a single molecule, cannabidiol, most often sold as an isolate, or included at levels too low to be biologically meaningful. This is a fundamental mismatch with how the ECS actually works. CBD has only weak affinity for the CB1 and CB2 receptors. Rather than activating them, it behaves as a negative allosteric modulator, subtly changing the shape of a receptor without switching the system on.67

An industry built on one molecule, used at doses too small to matter.

The result is a category of products that gesture toward the endocannabinoid system without truly engaging it: isolates that forfeit the synergy of the whole plant, and minor cannabinoids added at insignificant levels for the label rather than the effect. The science points the other way, toward the entourage effect, in which multiple cannabinoids acting together produce results greater than any isolate can.8

Our formulations are built on that premise. By combining a spectrum of rare cannabinoids, chosen for more direct receptor engagement and formulated at meaningful levels, they are designed to activate the ECS rather than merely brush against it. That is the core distinction between our topicals and the isolate-based products that dominate the shelf.

06 / Without the High

Why We Leave THC Out

A spectrum of cannabinoids does not require the one that intoxicates. Our formulations are deliberately THC-free, a choice that serves both safety and reach.

No High

Psychoactive Avoidance

THC is the primary psychoactive compound in cannabis, responsible for euphoria and for unwanted side effects. Leaving it out makes our products suitable for confident daily use, including by those with sensitive skin or professional obligations, with no psychoactive effect and no drug-test risk.

<0.3%

Regulatory Compliance

THC restrictions vary worldwide. By excluding it, our formulations align with FDA guidance for hemp-derived products containing less than 0.3% THC, avoid legal friction across jurisdictions, and remain suitable for broad international distribution.

Part III · Deeper Than Skin
07 / The Living Architecture

The Fascia: Where Skin Is Anchored

Skin is usually treated as two layers. It is, in truth, the visible surface of a single, continuous connective-tissue system that runs inward through the fascia.

And the fascia is not a bystander to the endocannabinoid system. Research has established that it carries the very same receptors our formulations are designed to engage, making the connective scaffolding beneath the skin an active participant in ECS signalling, not merely a neighbour to it.1921

SURFACE DEPTH Epidermis Dermis Superficial fascia Deep fascia Loose connective tissue: the gliding plane Muscle SKIN CB1 · CB2 · TRP · PPAR keratinocytes, sebocytes, fibroblasts FASCIA CB1 · CB2 receptors fasciacytes make hyaluronan → gliding Same system, deeper down.
The skin is the top of a continuous structure. The same endocannabinoid receptors found in the epidermis and dermis are present in the fascia beneath, where fasciacytes produce the body’s own hyaluronan.

What the Fascia Is

Moving inward from the surface, the body is layered: epidermis, dermis, then the superficial fascia within the hypodermis, the deep or muscular fascia, a plane of loose connective tissue, and finally muscle. The superficial fascia separates skin from the musculoskeletal system and lets the two glide independently, the quality that gives skin its mobility, suppleness, and youthful resilience. Far from inert packing, fascia is a dynamic, sensory, richly cellular tissue of fibroblasts, collagen, elastin, and a hydrated ground substance.

Fasciacytes & the Body’s Own Hyaluronan

The fascia contains a specialised cell, the fasciacyte, whose dedicated job is to produce hyaluronan, the same hyaluronic acid sold in serums.22 The hyaluronan fasciacytes secrete fills the spaces between tissues, dampens mechanical tension, and lubricates the planes between fascial layers so everything glides. When these cells falter, the layers begin to stick, glide is lost, and tissue feels stiff, tethered, and aged.23

The hyaluronic acid in a serum sits on top of the skin. The fascia makes its own.

This reframes one of skincare’s most familiar ingredients. Topical hyaluronic acid is the finished molecule, laid on the surface for a temporary effect. The fascia is the body’s own, internally regulated source of it. Supporting the cells that manufacture hyaluronan addresses hydration and glide at their origin, not as a coating, but as a capacity.

The Receptors Run Deeper Than the Dermis

Research has shown that fascial fibroblasts express both CB1 and CB2 receptors, and that the wider endocannabinoid system is present throughout fibroblasts and myofascial tissue.1921 The fascia, in other words, is wired into the same signalling network as the skin and the nervous system. The receptor machinery our formulations engage at the surface is also present in the connective tissue directly beneath it.

HA

Cannabinoids & Matrix Remodelling

Exposing human fascial cells to a cannabinoid triggered the rapid production of hyaluronan, within hours, alongside remodelling of the surrounding matrix. ECS engagement can prompt the tissue to make and organise its own hyaluronan: a regenerative model, not a cosmetic one.20

CB2

Inflammation & Fibrosis

The ECS helps balance supple tissue against fibrosis, the stiff, scar-like matrix of ageing. CB2 signalling is broadly anti-inflammatory and anti-fibrotic, aligning with the calming intent of our rare-cannabinoid blend.2425

The literature is careful here: the two receptors can pull in different directions. CB2 activation is consistently anti-inflammatory and anti-fibrotic, while CB1, in some settings, can promote fibrosis. This is part of why a balanced, multi-cannabinoid approach aimed at restoring healthy tone, rather than blunt, single-receptor stimulation, is the more sensible goal.25

The Body’s Richest Sensory Organ

Fascia is not passive wrapping. It is the most densely innervated tissue we have. The fascial network is estimated to contain on the order of 250 million nerve endings, rivalling the skin itself, with nociceptors and proprioceptors woven through it.28 Because the same endocannabinoid receptors sit within this richly sensory tissue, researchers have proposed that the endocannabinoid system may help modulate fascial inflammation and discomfort, which is part of why cannabinoids are now being studied in the context of myofascial comfort.192029

Densification, Not Just Scarring

There is an important and hopeful distinction in fascial science. Fibrosis is true scarring: disorganised collagen, hard to reverse. Densification is different: a change in the viscosity of the hyaluronan-rich layer that makes fascia stiff and sticky and costs it its glide, and it is considered readily reversible when hyaluronan is restored.29 Much of what reads on the surface as stiff, dull, “aged” tissue is densification, not permanent damage, precisely the state a system that renews the fascia’s own hyaluronan is positioned to address.

A Newly-Mapped Space

In 2018, researchers formally described the interstitium, a continuous, fluid-filled, collagen-supported space running through the fascia and connective tissues throughout the body, large enough that some have called it an overlooked organ.30 It is a reminder of how recently this terrain has been mapped, and how much of skin and tissue health lives in the connective layers conventional skincare has never addressed.

Topical hyaluronic acid applied to the surface stratum corneum no deeper signal SITS ON TOP · TEMPORARY The fascia’s own hyaluronan made within, on demand fasciacytes → hyaluronan MADE WITHIN · CONTINUOUS
Two different models of hydration: a finished molecule laid on the surface, versus supporting the cells that produce the body’s own hyaluronan from within.

Why It Shows on the Surface

How skin looks (its firmness, contour, smoothness, and freedom from dimpling) depends heavily on the connective architecture beneath it. The superficial fascia organises subcutaneous fat and anchors the skin, and the fibrous strands running through it are directly implicated in the dimpled look of cellulite. Well-hydrated, freely gliding, low-inflammation fascia reads at the surface as taut, mobile, resilient skin; stiff, dehydrated, fibrotic fascia reads as laxity and crepiness. By supporting fascial hydration and matrix balance through the ECS, topical phytocannabinoids may influence skin appearance at a structural level surface actives simply cannot reach.

08 / Why Skin Ages

Inflammaging and the System That Fades With It

Two of the clearest drivers of skin ageing are a slow, smouldering inflammation and a regulatory system that quietly winds down with the years.

Scientists call the first inflammaging: a chronic, low-grade inflammation that builds with age as cells become senescent and leak inflammatory signals into the tissue around them. In the skin, this background inflammation is now recognised as a central driver of lines, laxity, and dullness, not merely a side effect of getting older.31

The second is the ECS itself. Endocannabinoid tone declines with age: CB1 receptor density falls substantially across a lifespan and anandamide levels drop, so the very system that keeps inflammation in check becomes less able to do so, just when it is needed most.32 This is the core case for ECS-targeted care: rather than chasing the visible signs, it supports the regulatory tone that fades with age and lets inflammation take hold. Addressing the driver, not only the surface.

Part IV · Our Approach
09 / Getting In

Why Oil: The Delivery Problem

An active is only as good as its ability to reach its target. Cannabinoids are strongly lipophilic, fat-loving, with oil-water partition values around 6–7 and almost no water solubility.34 That single property dictates how they must be delivered.

The skin’s barrier is built from lipids, and the most viable route for a fat-soluble molecule is the intercellular lipid matrix between cells, with the sebaceous-follicle route as a second path inward.34 A water-based cream asks a fat-loving molecule to travel through a medium it resists; an oil-based vehicle works with the skin’s own chemistry, carrying cannabinoids into the lipid-rich layers where the ECS, in the dermis and the fascia below, actually lives. The delivery system is not a detail. For this class of molecule, it is half the mechanism.

10 / The Actives

The Rare Cannabinoids We Use

Where most products rely on a single molecule, our broad-spectrum, THC-free formulations bring together a spectrum of rare cannabinoids so they can work in concert, the entourage effect.8 Each contributes a distinct action in skin and connective tissue; together they cover far more of the ECS than any isolate can.111217

CBD

Cannabidiol

Calms inflammation and supports barrier repair; modulates TRPV1 and PPAR-γ to soothe reactive skin.16

CBG

Cannabigerol

Anti-inflammatory and antibacterial; in studies, reduces oxidative stress in fibroblasts and targets collagen and elastin genes.12

CBDA

Cannabidiolic Acid

A potent calming acid precursor that helps settle flare-ups, with high receptor affinity.

CBGA

Cannabigerolic Acid

Helps regulate inflammation and oxidative stress via the ECS and MAPK pathway, and supports DNA repair.11

CBC

Cannabichromene

Anti-inflammatory; shown to inhibit Th2 cytokines and JAK/STAT signalling in atopic-dermatitis models, and supports regeneration.14

CBN

Cannabinol

Supports cell-cycle balance and repair; shows TRPV1-mediated anti-inflammatory activity in keratinocytes and synergy with CBD.15

CBDV

Cannabidivarin

Helps reduce inflammation and oxidative stress and supports barrier stabilisation.

CBL

Cannabicyclol

Adds antimicrobial synergy and helps support compromised, reactive skin.

CBT

Cannabicitran

Associated with supporting orderly cell division and genomic integrity within the blend.

11 / The Difference

Regulation, Not Just Correction

Scientific research positions the ECS as a master regulator of skin homeostasis, influencing inflammation, barrier function, and cellular renewal.4 Conventional skincare is built on single-action ingredients that address a symptom without engaging that system. Our oil-based, multi-cannabinoid formulations are designed to do the opposite, to work with the ECS across both skin and fascia. Because the body operates as a lipid-based system within its tissues, oil-based delivery also integrates more seamlessly with the skin’s natural lipid matrix than water-based creams. Set side by side, the contrast is clear.

Retinol

vs. Our Approach

Accelerates turnover but can irritate and raise photosensitivity. We support renewal with anti-inflammatory action, and no photosensitivity.

HA

vs. Our Approach

Topical hyaluronic acid hydrates briefly at the surface. We engage the fasciacytes that make the body’s own hyaluronan, with deeper lipid-based delivery.

Vit C

vs. Our Approach

A potent antioxidant, but unstable and quick to oxidise. We offer stable, broad-spectrum antioxidant action plus anti-inflammatory and regenerative support, and cannabinoids such as CBG have been shown to work alongside stabilised vitamin C in UV-stressed skin cells.1213

Peptides

vs. Our Approach

Signal collagen with limited absorption and no regulatory reach. We support collagen through ECS pathways while modulating inflammation and repair.

Direct head-to-head clinical comparisons remain limited; these distinctions are drawn from mechanistic research on ECS modulation.

12 / The Benefits

What Our Topical Agents Deliver

01

Firmness & Radiance

CBDA and CBGA help support the skin’s youthful-looking firmness, while CBD and CBG help defend against oxidative stress, for visibly improved texture, clarity, and elasticity, and a calmer, more even-looking complexion.

02

Skin & the Tissue Beneath

Formulated to engage the endocannabinoid system not only in the skin but in the fascia, the connective tissue beneath it, helping skin look and feel supple, cushioned, and resilient rather than tight or tired.

03

Calm & Comfortable Feel

Helps reactive, sensitive skin look and feel calm and comfortable, soothing the appearance of redness and supporting a balanced complexion against everyday environmental stress.

04

Suppleness & Glide

By supporting the supple, gliding quality of healthy skin and the connective layers beneath, the formulations help skin feel mobile and cushioned, not stiff or dull.

05

Whole-System Balance

Designed to work with the body’s own regulatory system rather than override it, supporting a calm, balanced, healthy-looking complexion that reflects overall well-being.

13 / The Strategy

Why It Stands Apart

Beyond what each cannabinoid does in the skin, the approach itself is built to be broad, safe, and durable, a set of advantages no single-action ingredient can claim.

Holistic, Targeted Health

Addresses inflammation, ageing, and blemishes together through multi-cannabinoid synergy, rather than one symptom at a time.

Enhanced Efficacy

The entourage effect lets combined cannabinoids amplify one another beyond what any isolate achieves.

Natural, Not Synthetic

Plant-based and suitable for all skin types, aligned with clean-beauty values over synthetic retinoids or peptides.

Gentle & Tolerated

Irritant-free and well suited to sensitive skin, avoiding common allergens found in conventional formulations.

Ethical & Sustainable

Cruelty-free and responsibly sourced, meeting the expectations of conscious consumers.

Globally Compliant

THC-free by design, ensuring legal accessibility and broad international distribution.

14 / In Summary

The Whole Picture

A dysregulated ECS, worsened by stress, pollution, diet, and sleep deficits, impairs the body’s ability to maintain balance across both the skin and its connective tissue.

Our phytocannabinoid formulations are designed to help restore that balance: soothing inflammation, supporting the cellular machinery of renewal, and engaging the fascia where the body produces its own hyaluronan and organises its structural matrix. By acting on the master regulatory system rather than on surface symptoms alone, they aim to compensate for deficiency and support optimal function from the visible surface to the connective foundation beneath it, a holistic approach that conventional, single-target ingredients are not built to deliver.

A Note on Our Formulations

What We Make, and Why It Is Different

Reset ECS develops broad-spectrum, THC-free, oil-based topical formulations, including our pioneering facial serum and a complementary line of topical products, created specifically to support and engage the endocannabinoid system at the level of the skin and the connective tissue beneath it. Each is built around a spectrum of rare cannabinoids, formulated to harness the entourage effect, and delivered in a lipid base intended to integrate with the skin’s own matrix.

In contrast to the isolate-based or under-dosed products that define much of the category, our formulations are designed to engage the ECS directly rather than nominally. That difference (a true spectrum of cannabinoids, at meaningful levels, delivered in oil) is the whole point.

These are cosmetic formulations intended to support the appearance, comfort, and supple feel of healthy skin and the connective tissue beneath it. They are not intended to diagnose, treat, cure, or prevent any disease.

Part V · The Science
For the Clinically Curious

The Science, in More Depth

Everything so far stands on its own. What follows is the deeper molecular detail, written for practitioners and anyone who wants to see the mechanisms up close.

Three layers of evidence sit beneath the story above: the wider network of receptors cannabinoids engage in the skin, the master signalling pathways they influence, and how they help keep cell renewal in balance. None of it is required reading to understand the approach, but all of it is what the approach is built on.

15 / Beyond Two Receptors

The Receptor Orchestra

CB1 and CB2 are only the beginning. Phytocannabinoids speak to a whole orchestra of receptors in the skin, which is precisely why a single molecule can never do the job.

Much of the market talks as though the ECS were just CB1 and CB2. In the skin, cannabinoids also engage the TRP channels (TRPV1–4 and TRPA1) that govern heat, sensation, itch, barrier formation, and oil production; the PPAR nuclear receptors that steer inflammation and how skin cells mature; and signalling receptors such as GPR55 and 5-HT1A.2733 Different cannabinoids prefer different members of this orchestra, so a blend reaches targets no isolate can.

CB1 sensation & oil tone CB2 immunity & repair TRPV1–4 heat, barrier, sebum TRPA1 itch & irritation PPAR-γ/α inflammation & renewal GPR55 · 5-HT1A signalling & calm A SPECTRUM OF Phytocannabinoids
The skin’s cannabinoid-responsive receptors. A broad-spectrum blend engages the whole network; an isolate touches only part of it.
16 / The Pathways

The Switches the ECS Controls

Through its broad receptor network, the ECS interfaces with several of the master pathways that govern how skin behaves, the deeper control circuits that determine renewal, pigmentation, regeneration, and the response to stress. Rare phytocannabinoids can nudge these circuits toward balance in ways surface ingredients never touch.1118

mTOR

Growth & Proliferation

Overactive mTOR drives the excessive cell turnover seen in thickened, inflamed skin and in psoriasis. ECS activation can temper it, helping rebalance cellular metabolism and curb hyperplasia.10

MAPK
ERK

Renewal & Photo-Ageing

Governing maturation, pigmentation, and the UV response, this pathway is modulated by rare cannabinoids such as CBG and CBC to support anti-inflammatory and anti-photo-ageing effects.119

Wnt

Regeneration & Repair

Essential for stem-cell maintenance, wound healing, and follicle cycling, this pathway is supported via CB2, with cannabinoids implicated in countering fibrosis and scarring.25

PI3K
AKT

Survival & Resilience

Regulating cell survival and the response to oxidative stress, this pathway helps preserve fibroblast function and vascular integrity in ageing skin.16

17 / Renewal

The Cell Cycle, Kept in Balance

Healthy skin depends on the orderly progression of the cell cycle: G1 (growth), S (DNA synthesis), G2 (preparation), and M (division), the process behind repair, growth, and maintenance. By influencing the regulatory proteins and checkpoints that govern each stage, ECS modulation supports renewal while guarding against runaway proliferation, so the result is renewal that is regulated rather than merely accelerated.10

G1

Growth

As the cell grows and prepares to replicate, CBD and CBG help modulate cyclins and CDKs, inducing arrest where needed; the acid precursors CBDA and CBGA add receptor affinity.

S

DNA Synthesis

During replication, rare cannabinoids may support repair mechanisms and reduce oxidative damage, CBDV in particular, helping preserve genomic fidelity.

G2

Preparation

Before mitosis, CBN may help upregulate tumour-suppressor proteins such as p53 at the G2/M checkpoint, while CBC supports DNA-repair gene expression.

M

Division

During division itself, CBT and CBL may influence mitotic-spindle formation and chromosomal segregation, supporting accurate, healthy division.

The Regulators Behind the Phases

Cyclins and CDKs drive the cycle forward; CBD and CBG can downregulate them to support controlled turnover. Tumour suppressors such as p53 and Rb act as the brakes, with CBGA and CBDA binding effectively to promote the clearance of damaged cells. Proto-oncogenes, when mis-signalled, push proliferation; CBDV and CBC help modulate those pathways. At the checkpoints, G1/S and G2/M, cannabinoids such as CBGA, CBG, CBN, and CBD help ensure only healthy cells advance, while spindle-assembly stability guards against the chromosomal errors (aneuploidy) that accompany disordered division.

Reference / Glossary

Glossary

The Cannabinoids

CBD (Cannabidiol) Non-psychoactive; may reduce inflammation and support barrier repair. Modulates TRPV1 and PPAR-γ.
CBG (Cannabigerol) Anti-inflammatory and antibacterial; supports collagen and reduces cytokines such as IL-6 and TNF-α.
CBDA (Cannabidiolic Acid) Potent anti-inflammatory via COX-2; calms flare-ups. More bioavailable than CBD; acts on PPARs and 5-HT1A receptors.
CBGA (Cannabigerolic Acid) Regulates inflammation and oxidative stress and supports DNA repair; inhibits cytokines such as IL-1β and IL-8.
CBC (Cannabichromene) Anti-inflammatory and antibacterial; helps regulate sebum and supports regeneration and hair cycling.
CBN (Cannabinol) Supports cell-cycle regulation and repair; weak CB1 and strong CB2 affinity, with synergy alongside CBD.
CBDV (Cannabidivarin) Reduces inflammation and oxidative stress; supports barrier stabilisation. Modulates TRP channels.
CBL (Cannabicyclol) Stabilises formulations and provides antimicrobial synergy in compromised skin.
CBT (Cannabicitran) Supports mitotic regulation and DNA integrity; shares characteristics with terpenes acting on ion channels.

Fascia & Connective Tissue

Fascia The continuous web of connective tissue that surrounds and connects muscles, skin, and organs, providing structure, mobility, and gliding between layers.
Superficial Fascia The fibro-adipose layer within the hypodermis that separates skin from the musculoskeletal system and allows the two to slide independently.
Deep (Muscular) Fascia The denser fascial layer enveloping muscles; rich in fibroblasts and sensory innervation and responsive to ECS signalling.
Fasciacytes Specialised fascial fibroblasts (plumper, with central nuclei) dedicated to producing the hyaluronan that hydrates and lubricates the fascial layers.
Hyaluronan (Hyaluronic Acid) A hydrating molecule that fills intercellular spaces, dampens tension, and enables gliding; produced naturally by fasciacytes and fibroblasts.
Extracellular Matrix (ECM) The structural network of collagen, elastin, and ground substance around cells; its remodelling determines firmness, hydration, and resilience.
Myofascial Relating to the combined system of muscle and its surrounding fascia.

Pathways & Cellular Terms

mTOR Pathway Regulates cellular growth; overactivity is linked to hyperplasia in psoriasis and certain cancers.
Epidermal Hyperplasia Thickening of the skin in inflammatory disorders, producing scaling and redness.
MAPK/ERK Pathway Controls cell division and differentiation; dysregulated in ageing and pigmentation disorders.
ERK Phosphorylation Activates gene expression for survival and repair in response to stress.
Melanocytes Pigment-producing cells; central to pigmentation disorders such as melasma.
Wnt/β-Catenin Signalling Essential for regeneration and stem-cell maintenance; implicated in scarring and tumours when dysregulated.
β-Catenin Drives tissue-renewal genes in stem-cell maintenance.
PI3K/AKT Pathway Regulates survival and metabolism; linked to photo-ageing and angiogenesis.
Angiogenesis The formation of new blood vessels; essential for healing but aberrant in conditions such as rosacea.
Oxidative Stress An imbalance of reactive oxygen species that drives ageing, DNA damage, and inflammation.
Fibrotic Remodelling Excess, disorganised matrix deposition leading to stiffness and scarring; modulated in part by ECS signalling.
TRP Channels A family of skin ion channels (TRPV1–4, TRPA1) that sense heat, touch, and itch and are directly engaged by cannabinoids.
PPARs Nuclear receptors (PPAR-α/γ) that regulate inflammation, sebum, and skin-cell maturation; activated by several cannabinoids.
Sebocytes The cells of the sebaceous gland that produce sebum; their oil output is ECS-regulated, and CBD is sebostatic.
Densification A reversible rise in the viscosity of the fascia’s hyaluronan layer that reduces gliding and stiffens tissue, distinct from permanent fibrosis.
Interstitium A continuous, fluid-filled, collagen-supported space running through the fascia and connective tissues, formally described in 2018.
Inflammaging Chronic, low-grade inflammation that accumulates with age and drives skin ageing.
Cellular Senescence An irreversible halt in cell division; senescent cells secrete inflammatory signals (SASP) that age surrounding tissue.
Important Note. This document is for educational purposes only. It does not constitute medical advice and is not intended to diagnose, treat, cure, or prevent any disease. Our formulations have not undergone clinical trials; the research referenced below concerns phytocannabinoids, the endocannabinoid system, and connective tissue generally, and does not reflect testing on our specific products. Consult a healthcare professional before use. These statements have not been evaluated by the FDA.
How to read the evidence. The studies below span three levels of certainty: in vitro (cells in the laboratory), in vivo (animal models), and clinical (human studies). Most cannabinoid research in skin and fascia is still at the in-vitro and in-vivo stage; human clinical data is growing but remains limited.

What we don’t yet know. Our formulations have not undergone clinical trials. The mechanisms described here are well supported in the wider literature, but their translation into a specific cosmetic outcome for any individual is not guaranteed. This document is educational, not a therapeutic claim.

References

  1. Mechoulam R, Ben-Shabat S, et al. “Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.” Biochemical Pharmacology, 1995. PubMed
  2. Pacher P, Bátkai S, Kunos G. “The Endocannabinoid System as an Emerging Target of Pharmacotherapy.” Pharmacological Reviews, 2006. PMC
  3. Mackie K. “Cannabinoid Receptors: Where They Are and What They Do.” Journal of Neuroendocrinology, 2008. Wiley
  4. Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. “The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.” Trends in Pharmacological Sciences, 2009. PubMed
  5. Russo EB. “Clinical Endocannabinoid Deficiency Reconsidered.” Cannabis and Cannabinoid Research, 2016. Liebert / DOI
  6. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. “Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.” British Journal of Pharmacology, 2015. PMC
  7. Pertwee RG. “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: THC, CBD and THCV.” British Journal of Pharmacology, 2008. PMC
  8. Russo EB. “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.” British Journal of Pharmacology, 2011. Wiley
  9. Tóth BI, Dobrosi N, et al. “Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via CB1 and TRPV1.” Journal of Investigative Dermatology, 2011. PubMed
  10. Wilkinson JD, Williamson EM. “Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.” Journal of Dermatological Science, 2007. PubMed
  11. Tortolani D, Di Meo C, Standoli S, et al. (Maccarrone M). “Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway.” International Journal of Molecular Sciences, 2023. PMC
  12. Perez E, Fernandez JR, Fitzgerald C, et al. “In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.” Molecules, 2022. MDPI
  13. Gęgotek A, et al. “Proteomic analysis of the combined effects of cannabigerol and 3-O-ethyl ascorbic acid on kinase-dependent signalling in UVB-irradiated human keratinocytes.” Scientific Reports, 2024. Nature
  14. Kim KC, Jeong GH, Bang CH, Lee JH. “Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models.” International Journal of Molecular Sciences, 2024. PMC
  15. “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.” BioFactors, 2024. PMC
  16. Baswan SM, Klosner AE, Glynn K, et al. “Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders.” Clinical, Cosmetic and Investigational Dermatology, 2020. Dove Press
  17. “Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases: A Synthetic Review.” International Journal of Molecular Sciences, 2023. PMC
  18. “Cannabinoids and Their Receptors in Skin Diseases.” International Journal of Molecular Sciences, 2023. MDPI
  19. Fede C, Albertin G, Petrelli L, et al. “Expression of the endocannabinoid receptors in human fascial tissue.” European Journal of Histochemistry, 2016. PMC
  20. Fede C, Pirri C, Petrelli L, et al. (Stecco C). “Sensitivity of the Fasciae to the Endocannabinoid System: Production of Hyaluronan-Rich Vesicles and Potential Peripheral Effects of Cannabinoids in Fascial Tissue.” International Journal of Molecular Sciences, 2020. PMC
  21. McPartland JM, et al. “Expression of the endocannabinoid system in fibroblasts and myofascial tissues.” Journal of Bodywork and Movement Therapies, 2008. ScienceDirect
  22. Stecco C, Fede C, Macchi V, et al. “The fasciacytes: A new cell devoted to fascial gliding regulation.” Clinical Anatomy, 2018. Wiley
  23. Stecco C, Stern R, Porzionato A, et al. “Hyaluronan within fascia in the etiology of myofascial pain.” Surgical and Radiologic Anatomy, 2011. PubMed
  24. “Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts.” Rheumatology (Oxford), 2009. PubMed
  25. “The Potential Use of Cannabis in Tissue Fibrosis.” Frontiers in Cell and Developmental Biology, 2021. Frontiers
  26. Oláh A, Tóth BI, Biró T, et al. “Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes.” Journal of Clinical Investigation, 2014. JCI
  27. Caterina MJ. “TRP Channel Cannabinoid Receptors in Skin Sensation, Homeostasis, and Inflammation.” ACS Chemical Neuroscience, 2014. ACS
  28. “Evidence of a new hidden neural network into deep fasciae.” Scientific Reports, 2021. Nature
  29. Pavan PG, Stecco A, Stern R, Stecco C. “Painful Connections: Densification Versus Fibrosis of Fascia.” Current Pain and Headache Reports, 2014. Springer
  30. Benias PC, Wells RG, Sackey-Aboagye B, et al. “Structure and Distribution of an Unrecognized Interstitium in Human Tissues.” Scientific Reports, 2018. Nature
  31. “Cellular Senescence and Inflammaging in the Skin Microenvironment.” International Journal of Molecular Sciences, 2021. PMC
  32. “Age differences in endocannabinoid tone are ameliorated after recent cannabis use.” Scientific Reports, 2025. Nature
  33. “Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids.” Planta Medica, 2021. Thieme
  34. “The Skin and Natural Cannabinoids: Topical and Transdermal Applications.” Pharmaceuticals, 2023. PMC